Syndax Pharmaceuticals, Inc. (SNDX)
Full history for every metric is available with a Kvantra account
No price history available.
Key financial summary
Financials in USD| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Total revenue | $m | 2 | 140 | 0 | 0 | 24 | 172 | 252 | 316 |
| Operating profit | $m | -273 | -194 | ||||||
| Net profit | $m | -73 | 25 | -149 | -209 | -319 | -285 | -221 | -174 |
| EPS reported | $ | -3.29 | -2.52 | ||||||
| Operating cashflow per share | $ | -3.73 | -2.48 | ||||||
| Capex per share | $ | 0.00 | 0.00 | ||||||
| FCF per share | $ | -3.73 | -2.48 | ||||||
| Free cash flow | $m | -323 | -221 | ||||||
| Net debt | $m | -69 | 42 | ||||||
| Book value equity | $m | 65 | 15 | ||||||
| Book value per share | $ | 0.75 | 0.17 | ||||||
| Number of shares | m | 86.63 | 88.99 | ||||||
| DPS (TTM paid) | $ | 0.00 | 0.00 |
Financial summary
Financials in USD| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Value | |||||||||
| P/E TTM | x | - | - | ||||||
| P/B LTM | x | 28.16 | 120.54 | ||||||
| P/S LTM | x | 10.56 | 7.22 | ||||||
| P/FCF LTM | x | -5.63 | -8.24 | ||||||
| EV/EBITDA LTM | x | -8.07 | -15.02 | ||||||
| EV/Sales LTM | x | 11.79 | 7.98 | ||||||
| Earnings Yield LTM | % | -15.68% | -12.50% | ||||||
| FCF Yield | % | -17.76% | -12.14% | ||||||
| Quality | |||||||||
| ROE | % | -441.62% | -372.94% | ||||||
| ROIC | % | -66.60% | -32.10% | ||||||
| Operating margin | % | -1.58% | -77.05% | ||||||
| Gross margin | % | +95.96% | +97.47% | ||||||
| FCF/Sales | % | -187.50% | -87.64% | ||||||
| Growth and momentum | |||||||||
| EPS Growth YoY | % | - | - | ||||||
| Sales Growth YoY | % | +627.84% | +964.21% | ||||||
| Net Income Growth YoY | % | - | - | ||||||
| FCF Growth | % | - | - | ||||||
| Operating Profit Growth | % | - | - | ||||||
| Dividend and capital structure | |||||||||
| Dividend Yield | % | 0.00% | 0.00% | ||||||
| Dividend Growth | % | - | - | ||||||
| Payout Ratio | % | 0.00% | 0.00% | ||||||
| FCF/Debt | x | -0.93 | -0.37 | ||||||
| Net Debt/EBITDA | x | -0.84 | -1.87 | ||||||
| EBIT/Net interest | x | -8.08 | -2.27 | ||||||
| Net debt/market cap | % | +18.95% | +33.45% | ||||||
| Net debt/Equity | x | -1.06 | 2.75 | ||||||
| Gross debt/equity | x | 5.36 | 39.03 | ||||||
Price target estimates
Based on consensus from external analysts. Not Kvantra's opinion.
Ratings
Based on consensus from external analysts. Not Kvantra's opinion.
ESG
| Metric | 2024 | 2025 | 2026 |
|---|---|---|---|
| ESG-score | |||
| Environmental score | |||
| Social score | |||
| Governance score | |||
| Risk rating |
Company overview
Syndax Pharmaceuticals, Inc. operates as a clinical-stage biopharmaceutical firm focused on developing innovative therapies for cancer. Among its leading investigational products are SNDX-5613, currently undergoing Phase 1/2 clinical assessment, which targets the Menin-mixed lineage leukemia 1 protein interaction for treating MLL-rearranged (MLLr) and nucleophosmin 1 mutant acute myeloid leukemia (NPM1c AML). Another significant candidate is SNDX-6352, or axatilimab, a monoclonal antibody designed to block the colony stimulating factor 1 (CSF-1) receptor, intended for patients suffering from chronic graft versus host disease (cGVHD). The company is additionally progressing Entinostat. Syndax has also established strategic collaborations, including a research and development agreement with the National Cancer Institute, a clinical trial agreement with the Eastern Cooperative Oncology Group, and a license agreement with Kyowa Hakko Kirin Co., Ltd. Founded in 2005, Syndax Pharmaceuticals, Inc. maintains its corporate headquarters in Waltham, Massachusetts.
Similar companies
For informational purposes only. Kvantra provides data and quantitative analysis, not investment advice. KvantraRank is a mechanical model output. Analyst price targets and ratings are sourced from third parties and are not Kvantra recommendations. Past performance does not guarantee future results; all investments carry risk.
Syndax Pharmaceuticals, Inc. (SNDX)
No price history available.
Consensus from external analysts. Not Kvantra's opinion.
Based on consensus from external analysts. Not Kvantra's opinion.
Syndax Pharmaceuticals, Inc. operates as a clinical-stage biopharmaceutical firm focused on developing innovative therapies for cancer. Among its leading investigational products are SNDX-5613, currently undergoing Phase 1/2 clinical assessment, which targets the Menin-mixed lineage leukemia 1 protein interaction for treating MLL-rearranged (MLLr) and nucleophosmin 1 mutant acute myeloid leukemia (NPM1c AML). Another significant candidate is SNDX-6352, or axatilimab, a monoclonal antibody designed to block the colony stimulating factor 1 (CSF-1) receptor, intended for patients suffering from chronic graft versus host disease (cGVHD). The company is additionally progressing Entinostat. Syndax has also established strategic collaborations, including a research and development agreement with the National Cancer Institute, a clinical trial agreement with the Eastern Cooperative Oncology Group, and a license agreement with Kyowa Hakko Kirin Co., Ltd. Founded in 2005, Syndax Pharmaceuticals, Inc. maintains its corporate headquarters in Waltham, Massachusetts.
Unlock all fundamental data
Sign up for FreeUnlock all fundamental data
Sign up for Free